Literature DB >> 18246744

Stent implantation into the patent ductus arteriosus in cyanotic congenital heart disease with duct-dependent or diminished pulmonary circulation.

Ahmet Celebi1, Yalim Yalçin, Abdullah Erdem, Cenap Zeybek, Celal Akdeniz, Tuğçin Bora Polat.   

Abstract

We assessed the efficacy and safety of stent implantation into the ductus arteriosus in infants with cyanotic heart disease. Ten patients with duct-dependent or diminished pulmonary circulation underwent cardiac catheterization with the aim of stent implantation. Coronary stents of 3.5-4 mm in diameter were used and successfully implanted in eight. All patients in whom stent implantation was successful had adequate relief of their cyanosis and were discharged home. During a mean follow-up of 9.3 months (median 10 months), one patient had evidence of restenosis of the stent at five months. Re-dilatation of the stenosed stent was attempted but was unsuccessful and a modified left Blalock-Taussig shunt was placed surgically. Stent implantation of ductus arteriosus in neonates and infants with a duct-dependent pulmonary circulation is an effective and safe palliative procedure. It may be an alternative to surgical systemic-pulmonary artery shunt in a select group of patients.

Entities:  

Mesh:

Year:  2007        PMID: 18246744

Source DB:  PubMed          Journal:  Turk J Pediatr        ISSN: 0041-4301            Impact factor:   0.552


  2 in total

1.  Patent ductus arteriosus stenting in complex congenital heart disease: early and midterm results for a single-center experience at children hospital, Mansoura, Egypt.

Authors:  Mohamed Matter; Hala Almarsafawey; Mona Hafez; Gehan Attia; Mohamed-Magdy Abuelkheir
Journal:  Pediatr Cardiol       Date:  2012-12-13       Impact factor: 1.655

2.  Arterial duct stent versus surgical shunt for patients with duct-dependent pulmonary circulation: a meta-analysis.

Authors:  Dongxu Li; Xu Zhou; Mengsi Li
Journal:  BMC Cardiovasc Disord       Date:  2021-01-06       Impact factor: 2.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.